Skip to main content
Erschienen in: Clinical Reviews in Allergy & Immunology 1/2013

01.02.2013

Cardiovascular Risk in Rheumatoid Arthritis and Systemic Autoimmune Rheumatic Disorders: a Suggested Model of Preventive Strategy

verfasst von: Elena Bartoloni, Alessia Alunno, Onelia Bistoni, Roberto Gerli

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

The pathogenesis of accelerated cardiovascular damage commonly characterizing patients affected by systemic chronic inflammatory and autoimmune rheumatic disorders is quite complex and still not fully clarified. However, it is well accepted that a strong relationship between multiple factors, including both traditional cardiovascular risk factors and disease-related inflammatory and autoimmune mechanisms, may in part explain the precocious atherosclerotic vessel damage and the increased incidence of cardiovascular events. Nevertheless, although several recent studies focused their attention on the investigation of these complex mechanisms, data regarding possible preventive strategies aimed to reduce long-term cardiovascular risk in these subjects are still lacking and not conclusive. In this setting, the early introduction of evidence-based preventive measures for the correct management of patients with systemic autoimmune disorders would be of extreme importance to reduce subclinical atherosclerosis incidence and possible major cardiovascular events.
Literatur
1.
Zurück zum Zitat Holmqvist ME, Wedrén S, Jacobsson LTH et al (2010) Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis among patients diagnosed between 1995 and 2006. J Intern Med 268:578–585PubMedCrossRef Holmqvist ME, Wedrén S, Jacobsson LTH et al (2010) Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis among patients diagnosed between 1995 and 2006. J Intern Med 268:578–585PubMedCrossRef
2.
Zurück zum Zitat Shoenfeld Y, Gerli R, Doria A et al (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112:3337–3347PubMedCrossRef Shoenfeld Y, Gerli R, Doria A et al (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112:3337–3347PubMedCrossRef
3.
4.
Zurück zum Zitat Bartoloni Bocci E, Luccioli F, Angrisani C, Moscatelli S, Alunno A, Gerli R (2007) Accelerated atherosclerosis in systemic lupus erythematosus and other connective tissue diseases. Expert Rev Clin Immunol 3:531–541PubMedCrossRef Bartoloni Bocci E, Luccioli F, Angrisani C, Moscatelli S, Alunno A, Gerli R (2007) Accelerated atherosclerosis in systemic lupus erythematosus and other connective tissue diseases. Expert Rev Clin Immunol 3:531–541PubMedCrossRef
5.
Zurück zum Zitat Sarzi-Puttini P, Azteni F, Gerli R et al (2010) Cardiac involvement in systemic rheumatic diseases: an update. Autoimmun Rev 9:849–852PubMedCrossRef Sarzi-Puttini P, Azteni F, Gerli R et al (2010) Cardiac involvement in systemic rheumatic diseases: an update. Autoimmun Rev 9:849–852PubMedCrossRef
6.
Zurück zum Zitat Gerli R, Vaudo G, Bocci EB et al (2010) Functional impairment of arterial wall in primary Sjögren’s syndrome: combined action of immunological and inflammatory factors. Arthritis Care Res 62:712–718CrossRef Gerli R, Vaudo G, Bocci EB et al (2010) Functional impairment of arterial wall in primary Sjögren’s syndrome: combined action of immunological and inflammatory factors. Arthritis Care Res 62:712–718CrossRef
7.
Zurück zum Zitat Vaudo G, Bocci EB, Shoenfeld Y et al (2005) Precocious intima-media thickening in patients with primary Sjögren’s syndrome. Arthritis Rheum 52:3890–3897PubMedCrossRef Vaudo G, Bocci EB, Shoenfeld Y et al (2005) Precocious intima-media thickening in patients with primary Sjögren’s syndrome. Arthritis Rheum 52:3890–3897PubMedCrossRef
8.
Zurück zum Zitat Bartoloni E, Shoenfeld Y, Gerli R (2010) Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. Arthritis Care Res. doi:10.1002/acr.20322 Bartoloni E, Shoenfeld Y, Gerli R (2010) Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. Arthritis Care Res. doi:10.​1002/​acr.​20322
9.
Zurück zum Zitat Bartoloni E, Alunno A, Luccioli F et al (2010) Atherosclerotic vascular damage and rheumatoid arthritis: a complex but intriguing link. Expert Rev Cardiovasc Ther 8:1309–1316PubMedCrossRef Bartoloni E, Alunno A, Luccioli F et al (2010) Atherosclerotic vascular damage and rheumatoid arthritis: a complex but intriguing link. Expert Rev Cardiovasc Ther 8:1309–1316PubMedCrossRef
10.
Zurück zum Zitat Bartoloni E, Alunno A, Bistoni O, Gerli R (2010) How early is the atherosclerotic risk in rheumatoid arthritis? Autoimmun Rev 9:701–707PubMedCrossRef Bartoloni E, Alunno A, Bistoni O, Gerli R (2010) How early is the atherosclerotic risk in rheumatoid arthritis? Autoimmun Rev 9:701–707PubMedCrossRef
11.
Zurück zum Zitat Holmqvist ME, Wedrèn S, Jacobsson LT et al (2010) No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis. Results from two Swedish population-based rheumatoid arthritis cohorts. Arthritis Rheum 60:2861–2869CrossRef Holmqvist ME, Wedrèn S, Jacobsson LT et al (2010) No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis. Results from two Swedish population-based rheumatoid arthritis cohorts. Arthritis Rheum 60:2861–2869CrossRef
12.
Zurück zum Zitat Gabriel SE, Crowson CS, Kremers HM et al (2003) Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 48:54–58PubMedCrossRef Gabriel SE, Crowson CS, Kremers HM et al (2003) Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 48:54–58PubMedCrossRef
13.
Zurück zum Zitat Solomon DH, Goodson NJ, Katz JN et al (2006) Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 65:1608–1612PubMedCrossRef Solomon DH, Goodson NJ, Katz JN et al (2006) Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 65:1608–1612PubMedCrossRef
14.
Zurück zum Zitat Peters MJ, Symmons DP, McCarey D et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325–331PubMedCrossRef Peters MJ, Symmons DP, McCarey D et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325–331PubMedCrossRef
15.
Zurück zum Zitat Toms TE, Panoulas VF, Douglas KM et al (2010) Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis 69:683–688PubMedCrossRef Toms TE, Panoulas VF, Douglas KM et al (2010) Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis 69:683–688PubMedCrossRef
16.
Zurück zum Zitat Metsios G, Stavropoulos-Kalinoglou A, Sandoo A et al (2010) Vascular function and inflammation in rheumatoid arthritis: the role of physical activity. Cardiovasc Med J 4:89–96 Metsios G, Stavropoulos-Kalinoglou A, Sandoo A et al (2010) Vascular function and inflammation in rheumatoid arthritis: the role of physical activity. Cardiovasc Med J 4:89–96
17.
Zurück zum Zitat Libby P, Okamoto Y, Rocha V, Folco E (2010) Inflammation in atherosclerosis: transition from theory to practice. Circ J 74:213–220PubMedCrossRef Libby P, Okamoto Y, Rocha V, Folco E (2010) Inflammation in atherosclerosis: transition from theory to practice. Circ J 74:213–220PubMedCrossRef
18.
Zurück zum Zitat Turesson C, Matteson EL (2007) Cardiovascular risk factors, fitness and physical activity in rheumatic diseases. Curr Opin Rheumatol 19:190–196PubMedCrossRef Turesson C, Matteson EL (2007) Cardiovascular risk factors, fitness and physical activity in rheumatic diseases. Curr Opin Rheumatol 19:190–196PubMedCrossRef
19.
Zurück zum Zitat Volkmann ER, Grossman JM, Sahakian LJ et al (2010) Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus. Arthritis Care Res 62:258–265CrossRef Volkmann ER, Grossman JM, Sahakian LJ et al (2010) Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus. Arthritis Care Res 62:258–265CrossRef
20.
Zurück zum Zitat McMahon M, Grossman I, Skaggs B et al (2009) Dysfunctional proinflammatory high density lipoproteins confer increased risk for atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 60:2428–2437PubMedCrossRef McMahon M, Grossman I, Skaggs B et al (2009) Dysfunctional proinflammatory high density lipoproteins confer increased risk for atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 60:2428–2437PubMedCrossRef
21.
Zurück zum Zitat Steiner G, Urowitz M (2009) Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Arthritis Rheum 38:372–381CrossRef Steiner G, Urowitz M (2009) Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Arthritis Rheum 38:372–381CrossRef
22.
Zurück zum Zitat Gerli R, Bocci EB, Vaudo G, Marchesi S, Vitali C, Shoenfeld Y (2006) Traditional cardiovascular risk factors in primary Sjögren’syndrome: role of dyslipidemia [letter]. Rheumatology 45:1580–1581PubMedCrossRef Gerli R, Bocci EB, Vaudo G, Marchesi S, Vitali C, Shoenfeld Y (2006) Traditional cardiovascular risk factors in primary Sjögren’syndrome: role of dyslipidemia [letter]. Rheumatology 45:1580–1581PubMedCrossRef
23.
Zurück zum Zitat Abeles AM, Pillinger MH (2006) Statins are anti-inflammatory and immunomodulatory agents: a future in rheumatologic therapy. Arthritis Rheum 54:393–407PubMedCrossRef Abeles AM, Pillinger MH (2006) Statins are anti-inflammatory and immunomodulatory agents: a future in rheumatologic therapy. Arthritis Rheum 54:393–407PubMedCrossRef
24.
Zurück zum Zitat Tristano AG, Fuller K (2006) Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved. Int Immunopharmacol 6:1833–1846PubMedCrossRef Tristano AG, Fuller K (2006) Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved. Int Immunopharmacol 6:1833–1846PubMedCrossRef
25.
Zurück zum Zitat Bisoendial RJ, Stroes ES, Kastelein JJ, Tak PP (2010) Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins. Nat Rev Rheumatol 6:157–164PubMedCrossRef Bisoendial RJ, Stroes ES, Kastelein JJ, Tak PP (2010) Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins. Nat Rev Rheumatol 6:157–164PubMedCrossRef
26.
Zurück zum Zitat Jick SS, Choi H, Li L, McInnes IB, Sattar N (2009) Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 68:546–551PubMedCrossRef Jick SS, Choi H, Li L, McInnes IB, Sattar N (2009) Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 68:546–551PubMedCrossRef
27.
Zurück zum Zitat Paraskevas KI (2008) Statin treatment for rheumatoid arthritis: a promising novel indication. Clin Rheumatol 27:281–287PubMedCrossRef Paraskevas KI (2008) Statin treatment for rheumatoid arthritis: a promising novel indication. Clin Rheumatol 27:281–287PubMedCrossRef
28.
Zurück zum Zitat McCarey D, McInnes IB, Madhok R et al (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363:2015–2021PubMedCrossRef McCarey D, McInnes IB, Madhok R et al (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363:2015–2021PubMedCrossRef
29.
Zurück zum Zitat Lodi S, Evans SJ, Egger P, Carpenter J (2010) Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database. Br J Clin Pharmacol 69:85–94PubMedCrossRef Lodi S, Evans SJ, Egger P, Carpenter J (2010) Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database. Br J Clin Pharmacol 69:85–94PubMedCrossRef
30.
Zurück zum Zitat Petri M, Kiani AN, Post W et al (2006) Lupus Atherosclerosis Prevention Study (LAPS): randomized double blind placebo controlled trial of atorvastatin versus placebo. Arthritis Rheum 54:S520 Petri M, Kiani AN, Post W et al (2006) Lupus Atherosclerosis Prevention Study (LAPS): randomized double blind placebo controlled trial of atorvastatin versus placebo. Arthritis Rheum 54:S520
31.
Zurück zum Zitat Choy E, Sattar N (2009) Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 68:460–469PubMedCrossRef Choy E, Sattar N (2009) Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 68:460–469PubMedCrossRef
32.
Zurück zum Zitat Dixon WG, Watson KD, Lunt M et al (2007) Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis α therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56:2905–2912PubMedCrossRef Dixon WG, Watson KD, Lunt M et al (2007) Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis α therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56:2905–2912PubMedCrossRef
33.
Zurück zum Zitat Pérez-De-Lis M, Akasbi M, Sisó A et al (2010) Cardiovascular risk factors in primary Sjögren’s syndrome: a case–control study in 624 patients. Lupus 19:941–948PubMedCrossRef Pérez-De-Lis M, Akasbi M, Sisó A et al (2010) Cardiovascular risk factors in primary Sjögren’s syndrome: a case–control study in 624 patients. Lupus 19:941–948PubMedCrossRef
34.
Zurück zum Zitat Kitas G, Gabriel SE (2011) Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 70:8–14PubMedCrossRef Kitas G, Gabriel SE (2011) Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 70:8–14PubMedCrossRef
35.
Zurück zum Zitat Panoulas VF, Douglas KM, Smith JP et al (2009) Transforming growth factor-beta1 869T/C, but not interleukin-6-174G/C, polymorphism associates with hypertension in rheumatoid arthritis. Rheumatology 48:113–118PubMedCrossRef Panoulas VF, Douglas KM, Smith JP et al (2009) Transforming growth factor-beta1 869T/C, but not interleukin-6-174G/C, polymorphism associates with hypertension in rheumatoid arthritis. Rheumatology 48:113–118PubMedCrossRef
36.
Zurück zum Zitat Panoulas VF, Toms TE, Metsios GS et al (2010) Target organ damage in patients with rheumatoid arthritis: the role of blood pressure and heart rate. Atherosclerosis 209:255–260PubMedCrossRef Panoulas VF, Toms TE, Metsios GS et al (2010) Target organ damage in patients with rheumatoid arthritis: the role of blood pressure and heart rate. Atherosclerosis 209:255–260PubMedCrossRef
37.
Zurück zum Zitat Serelis J, Panagiotakos DB, Mavrommati M, Skopouli FN (2010) Cardiovascular disease is related to hypertension in patients with rheumatoid arthritis: a Greek Cohort Study. J Rheumatol. doi:10.3899/jrheum.100564 Serelis J, Panagiotakos DB, Mavrommati M, Skopouli FN (2010) Cardiovascular disease is related to hypertension in patients with rheumatoid arthritis: a Greek Cohort Study. J Rheumatol. doi:10.​3899/​jrheum.​100564
38.
Zurück zum Zitat Danowski A, Leitão N, de Azevedo M, de Souza Papi JA, Petri M (2009) Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 36:1195–1199PubMedCrossRef Danowski A, Leitão N, de Azevedo M, de Souza Papi JA, Petri M (2009) Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 36:1195–1199PubMedCrossRef
39.
Zurück zum Zitat Flammer AJ, Sudano I, Hermann F et al (2008) Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 117:2262–2269PubMedCrossRef Flammer AJ, Sudano I, Hermann F et al (2008) Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 117:2262–2269PubMedCrossRef
40.
Zurück zum Zitat Perry ME, Chee MM, Ferrell WR, Lockhart JC, Sturrock RD (2008) Angiotensin receptor blockers reduce erythrocyte sedimentation rate levels in patients with rheumatoid arthritis. Ann Rheum Dis 67:1646–1647PubMedCrossRef Perry ME, Chee MM, Ferrell WR, Lockhart JC, Sturrock RD (2008) Angiotensin receptor blockers reduce erythrocyte sedimentation rate levels in patients with rheumatoid arthritis. Ann Rheum Dis 67:1646–1647PubMedCrossRef
41.
Zurück zum Zitat Durán-Barragán S, McGwin G Jr, Vilá LM, Reveille JD, Alarcón GS (2008) Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus—results from LUMINA (LIX): a multiethnic US cohort. Rheumatology 47:1093–1096PubMedCrossRef Durán-Barragán S, McGwin G Jr, Vilá LM, Reveille JD, Alarcón GS (2008) Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus—results from LUMINA (LIX): a multiethnic US cohort. Rheumatology 47:1093–1096PubMedCrossRef
42.
Zurück zum Zitat Bussone G, Bérezné A, Pestre V, Guillevin L, Mouthon L (2010) The scleroderma kidney: progress in risk factors, therapy, and prevention. Curr Rheumatol Rep. doi:10.1007/s11926-010-0145-7 Bussone G, Bérezné A, Pestre V, Guillevin L, Mouthon L (2010) The scleroderma kidney: progress in risk factors, therapy, and prevention. Curr Rheumatol Rep. doi:10.​1007/​s11926-010-0145-7
43.
Zurück zum Zitat van Halm VP, Peters MJ, Voskuyl AE et al (2009) Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE investigation. Ann Rheum Dis 68:1395–1400PubMedCrossRef van Halm VP, Peters MJ, Voskuyl AE et al (2009) Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE investigation. Ann Rheum Dis 68:1395–1400PubMedCrossRef
44.
Zurück zum Zitat Parker B, Bruce IN (2010) The metabolic syndrome in systemic lupus erythematosus. Rheum Dis Clin North Am 36:81–97PubMedCrossRef Parker B, Bruce IN (2010) The metabolic syndrome in systemic lupus erythematosus. Rheum Dis Clin North Am 36:81–97PubMedCrossRef
45.
Zurück zum Zitat Sabio JM, Vargas-Hito J, Zamora-Pasadas M et al (2009) Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus. J Rheumatol 36:2204–2211PubMedCrossRef Sabio JM, Vargas-Hito J, Zamora-Pasadas M et al (2009) Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus. J Rheumatol 36:2204–2211PubMedCrossRef
46.
Zurück zum Zitat Shahin D, Eltoraby E, Mesbah A, Houssein M (2010) Insulin resistance in early untreated rheumatoid arthritis patients. Clin Biochem 43:661–665PubMedCrossRef Shahin D, Eltoraby E, Mesbah A, Houssein M (2010) Insulin resistance in early untreated rheumatoid arthritis patients. Clin Biochem 43:661–665PubMedCrossRef
47.
Zurück zum Zitat Chung CP, Oeser A, Solus JF et al (2008) Inflammation associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 58:2105–2112PubMedCrossRef Chung CP, Oeser A, Solus JF et al (2008) Inflammation associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 58:2105–2112PubMedCrossRef
48.
Zurück zum Zitat Venegas-Pont M, Sartori-Valinotti JC, Maric C et al (2009) Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol 296:R1282–R1289PubMedCrossRef Venegas-Pont M, Sartori-Valinotti JC, Maric C et al (2009) Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol 296:R1282–R1289PubMedCrossRef
49.
Zurück zum Zitat Zhao W, Thacker SG, Hodgin JB (2009) The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus. J Immunol 183:2729–2740PubMedCrossRef Zhao W, Thacker SG, Hodgin JB (2009) The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus. J Immunol 183:2729–2740PubMedCrossRef
50.
Zurück zum Zitat Kaprove Penn S, Kao AH, Schott LL et al (2010) Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 37:1136–1142CrossRef Kaprove Penn S, Kao AH, Schott LL et al (2010) Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 37:1136–1142CrossRef
51.
Zurück zum Zitat Morris SJ, Wasko MC, Antohe JL et al (2010) Hydroxychloroquine use is associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Rheum. doi:10.1002/acr.20393 Morris SJ, Wasko MC, Antohe JL et al (2010) Hydroxychloroquine use is associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Rheum. doi:10.​1002/​acr.​20393
52.
Zurück zum Zitat Jung H, Bobba R, Su J et al (2010) The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 62:863–868PubMedCrossRef Jung H, Bobba R, Su J et al (2010) The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 62:863–868PubMedCrossRef
53.
Zurück zum Zitat Turesson C, Jacobsson LT, Matteson E (2008) Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag 4:605–614PubMed Turesson C, Jacobsson LT, Matteson E (2008) Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag 4:605–614PubMed
54.
Zurück zum Zitat del Rincon I, O’Leary DH, Haas RW et al (2004) Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 50:3813–3822PubMedCrossRef del Rincon I, O’Leary DH, Haas RW et al (2004) Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 50:3813–3822PubMedCrossRef
55.
Zurück zum Zitat Westlake SL, Colebatch AN, Baird J (2010) The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 49:295–307PubMedCrossRef Westlake SL, Colebatch AN, Baird J (2010) The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 49:295–307PubMedCrossRef
56.
Zurück zum Zitat Hochberg MC, Johnston SS, John AK (2008) The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin 24:469–480PubMedCrossRef Hochberg MC, Johnston SS, John AK (2008) The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin 24:469–480PubMedCrossRef
57.
Zurück zum Zitat Ristic G, Lepic T, Glisic B et al (2010) Rheumatoid arthritis is an independent risk factor for increased carotid intima-media thickness: impact of anti-inflammatory treatment. Rheumatology 49:1076–1081PubMedCrossRef Ristic G, Lepic T, Glisic B et al (2010) Rheumatoid arthritis is an independent risk factor for increased carotid intima-media thickness: impact of anti-inflammatory treatment. Rheumatology 49:1076–1081PubMedCrossRef
58.
Zurück zum Zitat Georgiadis AN, Voulgari PV, Argyropoulou MI et al (2008) Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 38:13–19PubMedCrossRef Georgiadis AN, Voulgari PV, Argyropoulou MI et al (2008) Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 38:13–19PubMedCrossRef
59.
Zurück zum Zitat Angel K, Aarrestad Provan S, Lovahl Gulseth H, Mowinckel P, Kvien K, Atar D (2010) Tumor necrosis factor-α antagonists improve aortic stiffness in patients with inflammatory arthropathies. A controlled study. Hypertension 55:333.38CrossRef Angel K, Aarrestad Provan S, Lovahl Gulseth H, Mowinckel P, Kvien K, Atar D (2010) Tumor necrosis factor-α antagonists improve aortic stiffness in patients with inflammatory arthropathies. A controlled study. Hypertension 55:333.38CrossRef
60.
Zurück zum Zitat Kerekes G, Soltsèz P, Dèr H et al (2009) Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann N Y Acad Sci 1173:814–821PubMedCrossRef Kerekes G, Soltsèz P, Dèr H et al (2009) Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann N Y Acad Sci 1173:814–821PubMedCrossRef
61.
Zurück zum Zitat Gallaraga B, Belch JJ, Pullar T, Ogston S, Khan F (2010) Clinical improvement in rheumatoid arthritis is associated with healthier microvascualr function in patients who respond to antirheumatic therapy. J Rheumatol 37:521–528CrossRef Gallaraga B, Belch JJ, Pullar T, Ogston S, Khan F (2010) Clinical improvement in rheumatoid arthritis is associated with healthier microvascualr function in patients who respond to antirheumatic therapy. J Rheumatol 37:521–528CrossRef
62.
Zurück zum Zitat Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Llorca J (2010) Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Ann N Y Acad Sci 1193:153–159PubMedCrossRef Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Llorca J (2010) Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Ann N Y Acad Sci 1193:153–159PubMedCrossRef
63.
Zurück zum Zitat Gerli R, Schillaci G, Giordano A et al (2004) CD4+CD28null T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 109:2744–2748PubMedCrossRef Gerli R, Schillaci G, Giordano A et al (2004) CD4+CD28null T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 109:2744–2748PubMedCrossRef
64.
Zurück zum Zitat Gerli R, Vaudo G, Bartoloni Bocci E, Schillaci G, Bistoni O, Shoenfeld Y (2009) Different roles for anti-cyclic citrullinated peptide antibodies and CD4+CD28null cells in the acceleration of atherosclerosis in rheumatoid arthritis: comment on the article by Farragher et al. Arthritis Rheum 60:631–632PubMedCrossRef Gerli R, Vaudo G, Bartoloni Bocci E, Schillaci G, Bistoni O, Shoenfeld Y (2009) Different roles for anti-cyclic citrullinated peptide antibodies and CD4+CD28null cells in the acceleration of atherosclerosis in rheumatoid arthritis: comment on the article by Farragher et al. Arthritis Rheum 60:631–632PubMedCrossRef
65.
Zurück zum Zitat Gerli R, Bocci EB, Shoenfeld Y (2006) Effect of tumor necrosis factor α inhibition on CD28 surface expression on CD4+ T cells. Arthritis Rheum 54:3060–3061PubMedCrossRef Gerli R, Bocci EB, Shoenfeld Y (2006) Effect of tumor necrosis factor α inhibition on CD28 surface expression on CD4+ T cells. Arthritis Rheum 54:3060–3061PubMedCrossRef
66.
Zurück zum Zitat Kerekes G, Soltsez P, Der H et al (2009) Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis and lipid profile in rheumatoid arthritis. Clin Rheumatol 28:705–710PubMedCrossRef Kerekes G, Soltsez P, Der H et al (2009) Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis and lipid profile in rheumatoid arthritis. Clin Rheumatol 28:705–710PubMedCrossRef
67.
Zurück zum Zitat Bruce IN (2005) Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract Res Clin Rheumatol 19:823–838PubMedCrossRef Bruce IN (2005) Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract Res Clin Rheumatol 19:823–838PubMedCrossRef
Metadaten
Titel
Cardiovascular Risk in Rheumatoid Arthritis and Systemic Autoimmune Rheumatic Disorders: a Suggested Model of Preventive Strategy
verfasst von
Elena Bartoloni
Alessia Alunno
Onelia Bistoni
Roberto Gerli
Publikationsdatum
01.02.2013
Verlag
Humana Press Inc
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 1/2013
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-010-8251-x

Weitere Artikel der Ausgabe 1/2013

Clinical Reviews in Allergy & Immunology 1/2013 Zur Ausgabe

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.